Ionis Pharmaceuticals (NASDAQ:IONS) Posts Earnings Results, Beats Estimates By $0.46 EPS

Ionis Pharmaceuticals (NASDAQ:IONS) announced its earnings results on Wednesday. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.46, RTT News reports. Ionis Pharmaceuticals had a negative return on equity of 88.98% and a negative net margin of 44.58%. The company had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. During the same quarter in the prior year, the company earned $0.12 EPS. The firm’s revenue for the quarter was down 30.2% compared to the same quarter last year. Ionis Pharmaceuticals updated its FY 2025 guidance to EPS.

Ionis Pharmaceuticals Price Performance

IONS opened at $31.81 on Thursday. Ionis Pharmaceuticals has a twelve month low of $30.23 and a twelve month high of $52.34. The company’s 50-day moving average price is $33.82 and its two-hundred day moving average price is $38.50. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86.

Wall Street Analyst Weigh In

Several research firms have weighed in on IONS. Piper Sandler decreased their price target on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Wells Fargo & Company reduced their price objective on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Finally, William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Friday, December 20th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 33,445 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.63, for a total value of $1,091,310.35. Following the sale, the chief executive officer now directly owns 207,396 shares in the company, valued at $6,767,331.48. The trade was a 13.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Elizabeth L. Hougen sold 8,870 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $32.81, for a total value of $291,024.70. Following the transaction, the chief financial officer now directly owns 107,885 shares in the company, valued at $3,539,706.85. This represents a 7.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 110,609 shares of company stock worth $3,564,867 in the last quarter. Insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.